Major Depressive Disorder

Researchers investigated associations between medications with potential depressive symptom adverse effects and the level of depressive symptoms in a large survey study. Here’s what they found.

Here are some updates from the world of psychiatry throughout the month of October.

What is new in research on TMS?

In this CME article, review literature on SRI-related bleeding complications in patients with GI bleeding, malignancy, perioperative settings, pregnancy, and hormonal therapy.

Roger S. McIntyre, MD, FRCPC, and Carmen Kosicek, MSN, PMHNP-BC, discuss the future of MDD treatment and share closing thoughts.

Carmen Kosicek, MSN, PMHNP-BC, shares tips with patients about the use of zuranolone to treat MDD.

Due to ethical, knowledge, cost, and acceptability issues, deep brain stimulation is underutilized in disease states like treatment-resistant schizophrenia.

Experts in psychiatry review adverse effects of zuranolone, a γ-aminobutyric acid (GABA) receptor modulator, in the treatment of MDD.

Roger S. McIntyre, MD, FRCPC, comments on the paradigm shift of the frequency of dosing in the treatment of MDD, highlighting GABAergic modulating treatments, as well as the use of therapy to improve mental health.

Does early improvement in insomnia predict response to pharmacotherapy in psychotic depression? Authors performed a secondary analysis of a randomized clinical trial.

Carmen Kosicek, MSN, PMHNP-BC, shares considerations on the perception of mental health treatment among diverse cultures and ages within the United States.

Experts in psychiatry comment on the use of GABAa receptor modulators in the treatment of major depressive disorder (MDD), highlighting zuranolone.

From new research on treatment-resistant major depression to strategies for supporting trauma-affected refugee youth, here are highlights from the week in Psychiatric Times.

What is new in research on depression?

“Over 32 weeks of follow-up, the percentage of patients with remission, the percentage of patients with a treatment response, and the change in the MADRS score from baseline favored esketamine nasal spray.”

Roger S. McIntyre, MD, FRCPC; and Carmen Kosicek, MSN, PMHNP-BC; review the mechanism of action of newer therapies in MDD treatment.

Roger S. McIntyre, MD, FRCPC; and Carmen Kosicek, MSN, PMHNP-BC, discuss provider and patient communication about the time to onset of action of major depressive disorder (MDD) treatments and when the patient can expect to see a difference.

Get ready for our upcoming virtual, interactive conference with some highlights from 2022.

Is psilocybin a viable treatment for MDD? Researchers performed a phase 2, double blind trial of single-dose psilocybin in patients with treatment resistant depression.

From connections between cannabis use and schizophrenia to some non-psychiatric medications that may worsen symptoms of major depression, here are highlights from the week in Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of September.

Following a long path to approval, gepirone hydrochloride extended-release tablets (Exxua) is the first FDA-approved medication with this novel mechanism of action for adults with MDD.

Roger S. McIntyre, MD, FRCPC, discusses the history of psychiatry and the conventional treatment and response times, leading into the current treatment armamentarium for treatment of major depressive disorder (MDD).

Carmen Kosicek, MSN, PMHNP-BC, reviews the definition of “rapid-acting” therapies as well as their role in treating major depressive disorder (MDD).

The ongoing clinical trial is also studying the drug’s efficacy in the treatment of MDD.